Mateon Therapeutics (MATN) – Press Releases
-
MATEON ANNOUNCES INITIATION OF PHASE 1B CLINICAL TRIAL ON OT-101/IL-2 COMBINATION THERAPY FOR SOLID TUMORS
-
MATEON’S UPDATE ON C001 - GLOBAL STUDY FOR OT-101 AGAINST COVID-19
-
MATEON THERAPEUTICS AND WINDLAS BIOTECH PUBLISH PULMOHEAL™ CLINICAL DATA AGAINST COVID-19 IN PEER-REVIEWED JOURNALS
-
MATEON THERAPEUTICS AND WINDLAS BIOTECH LAUNCH INDIA’S FIRST COMBINED LUNG THERAPY AND AI TELEMEDICINE 360° SOLUTION TO TRANSFORM RESPIRATORY WELLNESS AT WWW.PULMOHEAL.COM
-
MATEON PARTNERED WITH CHOPRA FOUNDATION ON ARTIVEDA™
-
MATEON ANNOUNCES COMPLETION OF ARTI-19 AND PUBLICATION OF POSITIVE INTERIM DATA
-
MATEON LAUNCHES ITS AI TELEMEDICINE PLATFORM FOR POST MARKETING SURVEY TO SUPPORT ITS DRUG PRODUCT FOR INDIA, PULMOHEAL™
-
MATEON LAUNCHING MOBILE APP, ARTIHEALTH™, FOR REMOTE RESPIRATORY HEALTH ASSESSMENT
-
MATEON ANNOUNCES POSITIVE INTERIM RESULTS FROM ARTI-19 CLINICAL TRIAL EVALUATING COVID-19 THERAPEUTIC
-
MATEON’S GLOBAL STUDY FOR OT-101/ TGF-β INHIBITOR AGAINST COVID-19 ENROLLS AND TREATS ITS FIRST PATIENT
-
MATEON TO HOST VIRTUAL WEBINAR ADDRESSING COVID-19 AND THERAPIES AYURVEDA AND ARTEMISIA ON DECEMBER 16, 2020
-
DEVELOPMENT UPDATE FOR ARTIVEDA™/ARTISHIELD™ AGAINST COVID-19
-
MATEON PROVIDES CORPORATE UPDATE AND ANNOUNCES THIRD QUARTER 2020 FINANCIAL RESULTS
-
MATEON THERAPEUTICS AND WINDLAS BIOTECH ENTER INTO DEFINITIVE AGREEMENT TO COMMERCIALZE ARTIVEDA™ AGAINST COVID-19
-
MATEON’S C001- A GLOBAL PHASE 2 STUDY FOR OT-101 AGAINST COVID-19- RECEIVED CLEARANCE FOR PATIENT ENROLLMENT
-
MATEON TO HOST VIRTUAL SYMPOSIUM ADDRESSING COVID-19 ON NOVEMBER 11, 2020
-
MATEON ADVISOR DR. SUHAS KSHIRSAGAR WILL PRESENT AT DELHI UNIVERSITY ON ARTISHIELD™ FOR IMPROVING SYMPTOMS FOR COVID-19
-
MATEON’S PHASE 2 GLOBAL STUDY FOR OT-101/ TGF-β INHIBITOR AGAINST COVID-19 CLEARED FOR PATIENT ENROLLMENT IN ARGENTINA.
-
MATEON TO PARTICIPATE IN MERIDIAN CLINICAL TRIALS SUMMIT
-
MATEON TO PARTICIPATE IN BIO INVESTOR FORUM DIGITAL
-
MATEON ANNOUNCES FIRST PATIENT ENROLLED IN ARTI-19: A MULTICENTER INTERVENTIONAL STUDY OF ARTISHIELD™ AGAINST COVID-19
-
MATEON THERAPEUTICS TO INITIATE COMMERCIALIZATION OF ARTISHIELD™.
-
OT-101 PRESENTATION AT PHARMA FORUM 2020
-
FDA Granted Pediatric Disease Designation for OXi-4503
-
FDA Granted Pediatric Disease Designation for OXi-4503
-
Mateon’s Global Study for Artemisinin Intervention Against COVID-19 Cleared for Patient Enrollment in India
-
MATEON’S GLOBAL STUDY FOR ARTEMISININ INTERVENTION AGAINST COVID-19 CLEARED FOR PATIENT ENROLLMENT IN INDIA.
-
MATEON THERAPEUTICS REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS
-
MATEON THERAPEUTICS AND ABIOGENESIS TO INITIATE CLINICAL STUDY TO TEST ARTEMISININ AS A TREATMENT FOR COVID-19 IN INDIA
-
Mateon Therapeutics Closes $2.0 Million Financing
-
Mateon Therapeutics Closes $2.0 Million Financing
-
Mateon and Asili Research Alliance Enter Into Partnership for the Development of Artemisinin Against Covid-19
-
MATEON AND ASILI RESEARCH ALLIANCE ENTER INTO PARTNERSHIP FOR THE DEVELOPMENT OF ARTEMISININ AGAINST COVID-19
-
Mateon Therapeutics to fund observational studies of Artemisinin in developing countries
-
Mateon Therapeutics to fund observational studies of Artemisinin in developing countries.
-
Company expands its management team to accelerate the commercialization and development of OT-101 for COVID-19
-
Mateon Therapeutics Appoints Dr. Anthony Maida as Chief Clinical Officer - Translational Medicine
-
MATEON ANNOUNCES $2 MILLION FINANCING WITH GOLDEN MOUNTAIN PARTNERS TO CONDUCT CLINICAL TRIAL OF OT-101 AGAINST COVID19
-
MATEON IS SELECTED BY IBM WATSON HEALTH FOR THE USE OF IBM CLINICAL DEVELOPMENT SOLUTION AT NO COST FOR PHASE II CLINICAL TRIAL OF OT-101 FOR COVID-19
-
Mateon is Selected by IBM Watson Health for the Use of IBM Clinical Development Solution at No Cost for Phase II Clinical Trial of OT-101 for COVID-19
-
Mateon Therapeutics Selects IQVIA for its Randomized, Controlled, Multi-Center Clinical Study to Test OT-101 as a Treatment for COVID-19 Patients
-
Mateon Therapeutics Selects IQVIA for its Randomized, Controlled, Multi-Center Clinical Study to Test OT-101 as a Treatment for COVID-19 Patients
-
MATEON AND GMP COMPLETED RESEARCH AND SERVICE AGREEMENT
-
Mateon and GMP Completed Research and Service Agreement
-
Mateon Announces Achievement of Milestone Under Licensing of OT-101/IL-2 Combination to Autotelic BIO
-
Mateon Announces an Expansion to its Pharmaceutical Manufacturing AI Camera Grid by Including Contact Tracing to Ensure Worker Safety
-
Mateon Provides Update on OT-101
-
FDA Grants Pediatric Disease Designation for Mateon’s CA4P
-
Mateon Provides Update on its R&D Effort Against COVID-19
-
Mateon Announces the Filing of an IND with US FDA to Evaluate its Antisense Drug Candidate OT-101 in COVID-19 patients
Back to MATN Stock Lookup
